• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Suez Canal University Medical Journal
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 28 (2025)
Volume Volume 27 (2024)
Volume Volume 26 (2023)
Volume Volume 25 (2022)
Volume Volume 24 (2021)
Volume Volume 23 (2020)
Volume Volume 22 (2019)
Issue Issue 2
Issue Issue 1
Volume Volume 21 (2018)
Volume Volume 20 (2017)
Volume Volume 19 (2016)
Volume Volume 18 (2015)
Volume Volume 17 (2014)
Volume Volume 16 (2013)
Volume Volume 15 (2012)
Volume Volume 14 (2011)
Volume Volume 13 (2010)
Kamel, N. (2019). Platelet-rich Plasma: Three Decades and Ongoing, Do We Have a Conclusion?. Suez Canal University Medical Journal, 22(1), 1-8. doi: 10.21608/scumj.2019.42956
Noha M Kamel. "Platelet-rich Plasma: Three Decades and Ongoing, Do We Have a Conclusion?". Suez Canal University Medical Journal, 22, 1, 2019, 1-8. doi: 10.21608/scumj.2019.42956
Kamel, N. (2019). 'Platelet-rich Plasma: Three Decades and Ongoing, Do We Have a Conclusion?', Suez Canal University Medical Journal, 22(1), pp. 1-8. doi: 10.21608/scumj.2019.42956
Kamel, N. Platelet-rich Plasma: Three Decades and Ongoing, Do We Have a Conclusion?. Suez Canal University Medical Journal, 2019; 22(1): 1-8. doi: 10.21608/scumj.2019.42956

Platelet-rich Plasma: Three Decades and Ongoing, Do We Have a Conclusion?

Editorial, Volume 22, Issue 1, March 2019, Page 1-8  XML PDF (215.12 K)
DOI: 10.21608/scumj.2019.42956
View on SCiNiTO View on SCiNiTO
Author
Noha M Kamel email orcid
Clinical Pathology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Abstract
Blood components for non-transfusion uses have been the focus of researches in various clinical fields for the last thirty years. Platelet-rich plasma (PRP) can expedite healing, with minimal side effects. As a biologic autologous product, it is well-tolerated, and safe choice for many physicians and patients. Yet, no consensus has been reached regarding PRP preparation, needed volume, the use of an activator, number of sessions, and the period between the sessions in different clinical scenarios. Thus, further clinical studies are needed with higher level of evidence taking into consideration the optimization of these aspects. Up to date, there are many PRP preparation systems on the market with FDA clearance. Meanwhile, FDA has not attempted to regulate activated PRP. Determining the main bioactive components which are responsible for the clinical effects of PRP and the inter-individual variability of growth factors and cytokines production and the synergy of platelets count and growth factors will remain as major obstacles to achieve standardization of PRP. PRP is yet to become the standard of care; nevertheless, more clinical studies with longer periods of follow up to understand the best candidate and to determine the best ways to use it to improve healing; it may be an approved practice in the future. 
Keywords
platelet-rich plasma; growth factors; Platelets; applications; preparation methods
Statistics
Article View: 525
PDF Download: 839
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.